Relay Therapeutics (RLAY) Long-Term Investments (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Long-Term Investments data on file, last reported at $437.5 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $437.5 million, down 29.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $437.5 million (down 29.07% YoY), and the FY2025 annual result was $470.5 million, down 28.39% from the prior year.
• Long-Term Investments fell to $437.5 million in Q1 2026 per RLAY's latest filing, from $470.5 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $847.1 million in Q4 2022 and troughed at $437.5 million in Q1 2026.
• A 5-year average of $640.6 million and a median of $657.0 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2026: Long-Term Investments soared 80.22% in 2022, then slipped 29.07% in 2026.
• A 5-year view of Long-Term Investments shows it stood at $847.1 million in 2022, then dropped by 28.42% to $606.4 million in 2023, then grew by 8.36% to $657.0 million in 2024, then decreased by 28.39% to $470.5 million in 2025, then slipped by 7.02% to $437.5 million in 2026.
• Business Quant data shows RLAY's Long-Term Investments at $437.5 million in Q1 2026, $470.5 million in Q4 2025, and $504.9 million in Q3 2025.